Audited Financial Results for the Fourth Quarter and Financial year ended 31st March 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Hindustan Bio Sciences Ltd reported a net loss of Rs 7.89 lakhs for FY2026 (ended March 2026), a sharp reversal from a net profit of Rs 10.08 lakhs in FY2025. Revenue from operations declined by 9.4% to Rs 73.71 lakhs from Rs 81.33 lakhs year-on-year. For Q4 standalone, the company posted a loss of Rs 11.66 lakhs versus a profit of Rs 10.79 lakhs in Q4 FY2025. Total shareholders' funds stood at Rs 82.60 lakhs (down from Rs 90.49 lakhs) due to accumulated losses. The company reported negative EPS of Rs 0.08 for FY2026 compared to positive EPS of Rs 0.10 in the prior year. The statutory auditor VASG & Associates issued an unmodified (clean) opinion, and the board also approved the re-appointment of Mr. GBK Viswanadham as Internal Auditor for FY2026-27.
The company's transition from profit to loss and a 9.4% revenue decline signals deterioration in operating performance, likely negative for shareholders in the near term. However, the clean audit opinion and adequate internal controls provide some reassurance on financial reporting integrity.